Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.72 |
| ▸ | DPP4 | P27487 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11526870 | 0.98 | HSD11B1 (0.70) | HSD11B1DPP4LMNATSHRSLC6A4 | |
| SCHEMBL977926 | 0.98 | HSD11B1 (0.69) | HSD11B1DPP4LMNATSHRSLC6A4 | |
| SCHEMBL625584 | 0.94 | HSD11B1 (0.64) | HSD11B1DPP4LMNATSHRSLC6A4 | |
| SCHEMBL1361875 | 0.90 | TSHR (0.58) | HSD11B1DPP4LMNATSHRL3MBTL1 | |
| Di(Hydroxyethyl)Ether SCHEMBL28932504 | 0.85 | HSD11B1 (0.55) | HSD11B1DPP4LMNATSHRL3MBTL1 | |
| SCHEMBL11611383 | 0.85 | SLC6A4 (0.54) | HSD11B1DPP4LMNATSHRSLC6A4 | |
| SCHEMBL6583950 | 0.85 | HSD11B1 (0.54) | HSD11B1DPP4LMNASLC6A4SLC6A2 | |
| SCHEMBL17761202 | 0.85 | DPP4 (0.56) | HSD11B1DPP4LMNASLC6A4SLC6A2 | |
| SCHEMBL27690381 | 0.84 | LMNA (0.54) | HSD11B1DPP4LMNASLC6A4SLC6A2 | |
| SCHEMBL3542558 | 0.84 | HSD11B1 (0.66) | HSD11B1DPP4LMNATSHRSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3288527-B1 | N-ARALKYLCARBONYLDIAMINE COMPOUNDS AND PERSONAL CARE COMPOSITIONS COMPRISING THE SAME | UNILEVER PLC A COMPANY REGISTERED IN ENGLAND AND WALES UNDER COMPANY NO 41424 OF (GB) | 2020-02-19 | — | — | EP | disclosed |
| US-10307355-B2 | N-aralkylcarbonyldiamine compounds and personal care compositions comprising the same | CONOPCO, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180161260-A1 | N-ARALKYLCARBONYLDIAMINE COMPOUNDS AND PERSONAL CARE COMPOSITIONS COMPRISING THE SAME | CONOPCO, INC., D/B/A UNILEVER (US) | 2018-06-14 | — | — | US | disclosed |
| EP-3288527-A1 | N-ARALKYLCARBONYLDIAMINE COMPOUNDS AND PERSONAL CARE COMPOSITIONS COMPRISING THE SAME | Unilever PLC, a company registered in England and Wales under company no. 41424 of (GB) | 2018-03-07 | — | — | EP | disclosed |
| WO-2016173818-A1 | N-ARALKYLCARBONYLDIAMINE COMPOUNDS AND PERSONAL CARE COMPOSITIONS COMPRISING THE SAME | UNILEVER PLC (GB) | 2016-11-03 | — | — | WO | disclosed |
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| CN-101704810-A | Cycloalkyl inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO | 2010-05-12 | — | — | CN | disclosed |
| CN-100558697-C | Cycloalkyl inhibitors of potassium channel function | SQUIBB BRISTOL MYERS CO ICAGEN (US) | 2009-11-11 | — | — | CN | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| EP-0589665-B1 | 4,5,6,7-Tetrahydro-1H-imidazo 4,5-c pyridine-6-carboxylic acid amide derivatives as angiotensine II antagonistes | KUREHA CHEMICAL IND CO LTD (JP) | 1999-11-17 | — | — | EP | disclosed |
| US-5643904-A | Substituted hexahdryoazepinones and tetrahydrobenzazepinones | PFIZER INC. (US) | 1997-07-01 | — | — | US | disclosed |
| US-5484917-A | FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL DISORDERS, PAIN AND ANXIETY | PFIZER INC. (US) | 1996-01-16 | — | — | US | disclosed |
| US-5401736-A | Angiotensis II antagonists | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1995-03-28 | — | — | US | disclosed |
| EP-0589665-A2 | 4,5,6,7-Tetrahydro-1H-imidazo 4,5-c pyridine-6-carboxylic acid amide derivatives as angiotensine II antagonistes | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1994-03-30 | — | — | EP | disclosed |
| US-5239110-A | Phenylcyclohexanol derivatives as agents for treating CNS disorders | STERLING WINTHROP, INC. (US) | 1993-08-24 | — | — | US | disclosed |
| WO-1993015059-A1 | 3-PHENYLUREIDO-AZEPIN-2-ONES AND -BENZAZEPIN-2-ONES USEFUL AS CHOLECYSTOKININ ANTAGONISTS | PFIZER INC. (US) | 1993-08-05 | — | — | WO | disclosed |
| US-4021478-A | Preparation of carboxylic acids from glycidonitriles with ionic lewis acids | THE UPJOHN COMPANY (US) | 1977-05-03 | — | — | US | disclosed |
| US-3994964-A | Processes for the production of carboxylic acids from glycidonitriles | THE UPJOHN COMPANY (US) | 1976-11-30 | — | — | US | disclosed |
| US-3975431-A | Preparing carboxylic acids from glycidonitriles through enol acylates | THE UPJOHN COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10307355-B2 | N-aralkylcarbonyldiamine compounds and personal care compositions comprising the same | CUTA, AAAS, ACMSD | HSD11B1 4869/4885DPP4 2797/4885LMNA 372/4885 |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | HSD11B1 3987/4885DPP4 2095/4885LMNA 1535/4885 |
| US-20180161260-A1 | N-ARALKYLCARBONYLDIAMINE COMPOUNDS AND PERSONAL CARE COMPOSITIONS COMPRISING THE SAME | CUTA, ACMSD, KRT18 | HSD11B1 4800/4885DPP4 1940/4885LMNA 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.